Beta-Blocker Selection for Panic Attacks

Primary Recommendation

Propranolol is the preferred agent for panic disorder when beta-blockade is indicated, as it has the most extensive evidence base for treating anxiety-related conditions and is specifically mentioned in guidelines for symptom relief in panic disorder 1
The typical approach involves combining propranolol with cognitive behavior therapy and/or selective serotonin reuptake inhibitors and/or benzodiazepines, as beta-blockers alone are insufficient for comprehensive panic disorder management 1
The American College of Cardiology recommends considering propranolol as a treatment option for panic disorder, as it provides symptomatic relief of somatic manifestations like palpitations and tremor 1

If the patient has asthma or significant reactive airway disease, propranolol is contraindicated and metoprolol becomes the only reasonable option at very low doses with close respiratory monitoring 2
For patients with asthma, metoprolol at very low initial doses (12.5 mg orally) is the only acceptable beta-blocker if beta-blockade is absolutely necessary 3, 2
The American College of Cardiology recommends considering non-dihydropyridine calcium channel blockers as alternative therapy rather than any beta-blocker in asthmatic patients 2

Metoprolol is beta-1 selective (cardioselective) and safer in patients with pulmonary disease, with an initial dose of 12.5-25 mg orally every 6 hours 3
Atenolol has lower beta-1 selectivity compared to metoprolol and may worsen pulmonary function in COPD, making it a less preferred option 4
The American College of Cardiology recommends avoiding atenolol in COPD patients due to its lower beta-1 selectivity 4

Do not use propranolol as monotherapy for panic disorder—it must be combined with psychological therapy and/or other pharmacotherapy 1
Do not use any beta-blocker in patients with marked first-degree AV block (PR >0.24s), second- or third-degree AV block without a pacemaker, or severe bradycardia (HR <50 bpm) 3
Do not assume all beta-blockers are equally safe in pulmonary disease—the distinction between cardioselective and nonselective agents is clinically crucial 2